A detailed history of Main Management ETF Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Main Management ETF Advisors, LLC holds 14,744 shares of CRSP stock, worth $600,375. This represents 0.03% of its overall portfolio holdings.

Number of Shares
14,744
Holding current value
$600,375
% of portfolio
0.03%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$44.62 - $62.75 $657,877 - $925,186
14,744 New
14,744 $693,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.18B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Main Management ETF Advisors, LLC Portfolio

Follow Main Management ETF Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Main Management ETF Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Main Management ETF Advisors, LLC with notifications on news.